Tyra Biosciences (NASDAQ: TYRA) details 2026 shareholder meeting voting outcomes

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

8-K Event Classification

Key Figures

Key Terms

What did Tyra Biosciences (TYRA) report from its 2026 Annual Meeting?

Which directors were elected at Tyra Biosciences (TYRA) 2026 Annual Meeting?

How many votes did the Tyra Biosciences (TYRA) 2026 proposal receive?

What were the vote totals for Tyra Biosciences (TYRA) director Habib J. Dable?

How did stockholders vote on director Susan Moran at Tyra Biosciences (TYRA)?

What were the voting results for Tyra Biosciences (TYRA) director Robert More?

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Tyra Biosciences, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 28, 2026. Stockholders elected three directors: Habib J. Dable, Susan Moran, M.D., M.S.C.E., and Robert More. Each nominee received over 41 million votes in favor, with 8,377,977 broker non-votes recorded on each director item.

Stockholders also approved another meeting proposal with 53,092,820 votes for, 1,316 against, and 3,246 abstentions, and no broker non-votes.

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Votes for Habib J. Dable: 44,242,803 votes Votes for Susan Moran: 44,529,688 votes Votes for Robert More: 41,013,686 votes +4 more

7 metrics

Votes for Habib J. Dable 44,242,803 votes Director election at 2026 Annual Meeting

Votes for Susan Moran 44,529,688 votes Director election at 2026 Annual Meeting

Votes for Robert More 41,013,686 votes Director election at 2026 Annual Meeting

Broker non-votes on director items 8,377,977 votes Each director election at 2026 Annual Meeting

Votes for other proposal 53,092,820 votes Stockholder proposal at 2026 Annual Meeting

Votes against other proposal 1,316 votes Stockholder proposal at 2026 Annual Meeting

Abstentions on other proposal 3,246 votes Stockholder proposal at 2026 Annual Meeting

Annual Meeting of Stockholders, broker non-votes, emerging growth company, Common Stock, par value $0.0001 per share, +1 more

5 terms

Annual Meeting of Stockholders financial

"Tyra Biosciences, Inc. (the Company) held its 2026 Annual Meeting of Stockholders (the 2026 Annual Meeting) on May 28, 2026."

broker non-votes financial

"the number of broker non-votes with respect to each matter, as applicable."

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

emerging growth company regulatory

"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Nasdaq Global Select Market financial

"Common Stock, par value $0.0001 per share | | TYRA | | Nasdaq Global Select Market"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/02/2026 - 04:01 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 28, 2026

Tyra Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-40800

83-1476348

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)


2656 State Street
Carlsbad, California		92008
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (619) 728-4760

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share

TYRA

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07

Submission of Matters to a Vote of Security Holders.

Tyra Biosciences, Inc. (the Company) held its 2026 Annual Meeting of Stockholders (the 2026 Annual Meeting) on May 28, 2026. The following is a brief description of each matter voted upon at the 2026 Annual Meeting and the number of votes cast for, withheld or against, the number of abstentions and the number of broker non-votes with respect to each matter, as applicable.

The election of three directors to serve as Class II directors for a three-year term to expire at the 2029 Annual Meeting of Stockholders. The following three Class II directors were elected by the votes indicated:


	For		Withheld		Broker Non-Votes
Habib J. Dable		44,242,803		476,602		8,377,977
Susan Moran, M.D., M.S.C.E.		44,529,688		189,717		8,377,977
Robert More		41,013,686		3,705,719		8,377,977

2.	The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The appointment was ratified by the votes indicated:


For	Against	Abstain	Broker Non-Votes
53,092,820	1,316	3,246	–

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

Tyra Biosciences reported the voting results from its 2026 Annual Meeting of Stockholders held on May 28, 2026. Stockholders elected three directors and approved another proposal by wide margins, with millions of votes cast in favor and minimal opposition or abstentions.

Stockholders elected Habib J. Dable, Susan Moran, M.D., M.S.C.E., and Robert More as directors. Each nominee received more than 41 million votes for and had 8,377,977 broker non-votes recorded, reflecting strong support relative to withheld votes for each director candidate.

One meeting proposal received 53,092,820 votes for, 1,316 against, and 3,246 abstentions, with no broker non-votes. This indicates overwhelming stockholder approval based on the reported vote distribution in the meeting results disclosed by the company.

Habib J. Dable received 44,242,803 votes for election and 476,602 votes withheld, along with 8,377,977 broker non-votes. These results show a large majority of votes cast in favor compared with the relatively small number of withheld votes for this director.

Susan Moran, M.D., M.S.C.E., received 44,529,688 votes for and 189,717 votes withheld, plus 8,377,977 broker non-votes. The voting results show very strong stockholder support, with withheld votes representing a small fraction of the votes cast on her election.

Robert More received 41,013,686 votes for election and 3,705,719 votes withheld, together with 8,377,977 broker non-votes. While withheld votes were higher than for other nominees, a clear majority of votes cast still supported his election to the board.

TYRA BIOSCIENCES, INC.

Date: June 2, 2026

/s/ Ali Fawaz

General Counsel and Secretary

3 documents